The role and efficacy of sirolimus albumin-bound nanoparticle injection (FYARRO)

Sirolimus albumin-bound nanoparticle injection (FYARRO) is an inhibitor of the mechanistic target of rapamycin kinase (mTOR) and is used to treat malignant perivascular epithelioid cell tumor (PEComa). Malignant PEComa is a rare, aggressive soft tissue sarcoma. Malignant PEComas often contain TSC1 and/or TSC2 gene mutations, leading to activation of the mTOR pathway. In tumor cells, abnormally activated mTOR sends signals that stimulate tumor cells to grow, metastasize, and invade new healthy tissue.

Sirolimus slows tumor growth by inhibitingmTOR. The sirolimus in Sirolimus Albumin-Bound Nanoparticle Injection is bound to human albumin to enhance drug delivery into tumor cells. Fyarro is administered as an intravenous infusion over 30 minutes on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. Sirolimus albumin-bound nanoparticle injectionmay cause serious adverse reactions, including stomatitis, myelosuppression, infection, hypokalemia and hyperglycemia, ILD/non-infectious pneumonia, bleeding and allergic reactions.

The original drug of sirolimus albumin-bound nanoparticle injection has not yet been marketed in China, so it is not included in medical insurance. The US version of sirolimus albumin-bound nanoparticle injection Original drug, specifications The price of each 100mg tube may be around RMB 60,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Sirolimus Albumin-Bound Nanoparticle Injection on the market. For more drug information and specific prices, please consult Yaode Medical Consultants.